NantKwest launches phase I clinical trial with targeted PD-L1 t-haNK cell therapy
NantKwest announced the company’s PD-L1 t-haNK investigational new drug application has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid cancers. June 24, 2019